ERBB2 and breast cancer: Very few early trials were adequately powered to assess both endpoints; however, overall, almost all combination chemotherapies that improved pCR rates (by incorporating a taxane-based, carboplatin-based, HER2-targeted therapy or pembrolizumab) also improved EFS in BC studies23,24.